BRAF--a new player in hematological neoplasms.
BRAF oncogenic kinase has become a target for specific therapy in oncology. Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib. Our knowledge regarding the role of mutated BRAF in hematological malignancies has grown quickly as a result of new genetic techniques such as next-generation sequencing. This review summarizes current knowledge regarding the role of BRAF in lymphoid and myeloid neoplasms, with a focus on hairy-cell leukemia, Langerhans cell histiocytosis, and Erdheim-Chester disease.
Department of Immunology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
Marcin M
MM
Machnicki
Department of Immunology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland. Electronic address: tomasz.stoklosa@wum.edu.pl.
Tomasz
T
Stoklosa
D000818:Animals; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism*
C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
BRAF kinase; Histiocytosis; Leukemia; V600E mutation